Literature DB >> 15410992

PARA-AMINOSALICYLIC acid treatment in pulmonary tuberculosis.

.   

Abstract

Entities:  

Keywords:  TUBERCULOSIS, PULMONARY; p-AMINO-SALICYLIC ACID

Mesh：

Substances：

Year:  1950        PMID： 15410992

Source DB:  PubMed          Journal:  Am Rev Tuberc        ISSN： 0096-0381


× No keyword cloud information.
  10 in total

Review 1.  Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis.

Authors:  Kelly E Dooley; Carole D Mitnick; Mary Ann DeGroote; Ekwaro Obuku; Vera Belitsky; Carol D Hamilton; Mamodikoe Makhene; Sarita Shah; James C M Brust; Nadza Durakovic; Eric Nuermberger
Journal:  Clin Infect Dis       Date:  2012-05-21       Impact factor: 9.079

Review 2.  The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance.

Authors:  Ahmed A Abulfathi; Peter R Donald; Kim Adams; Elin M Svensson; Andreas H Diacon; Helmuth Reuter
Journal:  Br J Clin Pharmacol       Date:  2020-06-21       Impact factor: 4.335

3.  Sputum volume predicts sputum mycobacterial load during the first 2 weeks of antituberculosis treatment.

Authors:  Miriam N Karinja; Tonya M Esterhuizen; Sven O Friedrich; Andreas H Diacon
Journal:  J Clin Microbiol       Date:  2014-12-31       Impact factor: 5.948

4.  Dose regimen of para-aminosalicylic acid gastro-resistant formulation (PAS-GR) in multidrug-resistant tuberculosis.

Authors:  Yves Kibleur; Hervé Brochart; Hendrik S Schaaf; Andre H Diacon; Peter R Donald
Journal:  Clin Drug Investig       Date:  2014-04       Impact factor: 2.859

5.  Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).

Authors:  Pooja V Hegde; Michael D Howe; Matthew D Zimmerman; Helena I M Boshoff; Sachin Sharma; Brianna Remache; Ziyi Jia; Yan Pan; Anthony D Baughn; Veronique Dartois; Courtney C Aldrich
Journal:  Eur J Med Chem       Date:  2022-02-19       Impact factor: 6.514

6.  Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.

Authors:  Anneke C Hesseling; Paolo Denti; Louvina E van der Laan; Anthony J Garcia-Prats; H Simon Schaaf; Maxwell Chirehwa; Jana L Winckler; Jun Mao; Heather R Draper; Lubbe Wiesner; Jennifer Norman; Helen McIlleron; Peter R Donald
Journal:  Antimicrob Agents Chemother       Date:  2022-05-04       Impact factor: 5.938

7.  Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.

Authors:  Vanessa Mathys; René Wintjens; Philippe Lefevre; Julie Bertout; Amit Singhal; Mehdi Kiass; Natalia Kurepina; Xiao-Ming Wang; Barun Mathema; Alain Baulard; Barry N Kreiswirth; Pablo Bifani
Journal:  Antimicrob Agents Chemother       Date:  2009-02-23       Impact factor: 5.191

8.  Down and almost out in Scotland: George Orwell, tuberculosis and getting streptomycin in 1948.

Authors:  Hilda Bastian
Journal:  J R Soc Med       Date:  2006-02       Impact factor: 18.000

9.  The MRC randomized trial of streptomycin and its legacy: a view from the clinical front line.

Authors:  J Crofton
Journal:  J R Soc Med       Date:  2006-10       Impact factor: 18.000

10.  Utility of para-aminosalicylic acid in drug-resistant tuberculosis: Should it be classified as Group D3 or Group C?

Authors:  Unnati Desai; Jyotsna M Joshi
Journal:  Lung India       Date:  2018 Nov-Dec
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.